The Food and Drug Administration’s (FDA’s) Vaccines and Related Biological Products Advisory Committee has announced an upcoming meeting that will include updates on research programs concerning bacterial polysaccharides and matters relating to groups of meningococcal vaccines. FDA plans to make background material available to the public no later than two business days before the April 6-7, 2011, meeting in Washington, D.C., and Gaithersburg, Maryland.

Agenda items will include (i) “updates of the research programs in the Laboratory of Bacterial Polysaccharides, Division of Bacterial, Parasitic, and Allergenic Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, FDA”; (ii) briefings “on the use of immunological markers for demonstration of effectiveness of meningococcal serogroups A, C, Y, and W-135 conjugate vaccines administered to children less than 2 years of age”; and (iii) “approaches to licensure of meningococcal serogroup B vaccines.”